» Articles » PMID: 31269428

Macrophages and Metabolism in the Tumor Microenvironment

Overview
Journal Cell Metab
Publisher Cell Press
Date 2019 Jul 4
PMID 31269428
Citations 751
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) constitute a plastic and heterogeneous cell population of the tumor microenvironment (TME) that can account for up to 50% of some solid neoplasms. Most often, TAMs support disease progression and resistance to therapy by providing malignant cells with trophic and nutritional support. However, TAMs can mediate antineoplastic effects, especially in response to pharmacological agents that boost their phagocytic and oxidative functions. Thus, TAMs and their impact on the overall metabolic profile of the TME have a major influence on tumor progression and resistance to therapy, de facto constituting promising targets for the development of novel anticancer agents. Here, we discuss the metabolic circuitries whereby TAMs condition the TME to support tumor growth and how such pathways can be therapeutically targeted.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.


Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.


Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


Inherent PD-L1 22C3 Expression in Alveolar Macrophages Impacts the Combined Positive Score Status in Breast Cancer With Pulmonary Metastasis.

Cha Y, Kim H, Koo J Thorac Cancer. 2025; 16(5):e70004.

PMID: 40051246 PMC: 11885796. DOI: 10.1111/1759-7714.70004.


Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes.

Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X Cancer Cell Int. 2025; 25(1):77.

PMID: 40045297 PMC: 11881339. DOI: 10.1186/s12935-025-03680-7.